Galena Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Galena Pharma's estimated annual revenue is currently $2.5M per year.
- Galena Pharma's estimated revenue per employee is $98,000
Employee Data
- Galena Pharma has 25 Employees.
- Galena Pharma grew their employee count by 14% last year.
Galena Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.1M | 101 | 5% | N/A | N/A |
#2 | $1.6M | 19 | -71% | N/A | N/A |
#3 | $212.8M | 1063 | 5% | $65M | N/A |
#4 | $6.8M | 54 | 8% | N/A | N/A |
#5 | $12.9M | 92 | 2% | $23.1M | N/A |
#6 | $1M | 12 | N/A | N/A | N/A |
#7 | $106.5M | 599 | -17% | $2.3M | N/A |
#8 | $35.6M | 231 | 6% | N/A | N/A |
#9 | $38.3M | 249 | 5% | N/A | N/A |
#10 | $45M | 299 | -4% | $102.6M | N/A |
What Is Galena Pharma?
Galena Pharma Oy is a Finnish pharmaceutical factory specialising in contract manufacturing and packaging services. Our production facilities in Kuopio manufacture various products relating to health and well-being under contract: pharmaceuticals, medical devices, nutritional supplements, cosmetics, animal care products and sports products.
keywords:N/A
N/A
Total Funding
25
Number of Employees
$2.5M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Galena Pharma News
ImmunoBiology Ltd. Galena Biopharma. Table of Content: Market Definition and Overview; Research Method and Logic; Market Competition Analysis...
... Aop Orphan Pharmaceuticals AG, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Incyte Corp, Italfarmaco SpA, MEI Pharma Inc, PharmaEssentia Corp.
Galena Biopharma. Bavarian Nordic. Celldex Therapeutics. ImmunoCellular Therapeutics. Takeda. Spectrum Pharmaceuticals. GlaxoSmithKline.
Other Companies in Kuopio
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.3M | 30 | -23% | N/A |
#2 | N/A | 35 | 59% | N/A |
#3 | $8.4M | 39 | 0% | N/A |
#4 | $12.7M | 67 | 24% | N/A |
#5 | N/A | 70 | 32% | N/A |